BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The consensus price target hints at a 67.4% upside potential for BridgeBio Pharma (BBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does BridgeBio Pharma (BBIO) Have the Potential to Rally 67.36% as Wall Street Analysts Expect?

–Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) continues to have high operating fidelity; month 30 topline registrational data are expected to be announced in mid-2023

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will BridgeBio Pharma (BBIO) Report Negative Q4 Earnings? What You Should Know

BridgeBio has some very significant price catalysts arriving in 2023 promising substantial upside should they be positive. Most important is Phase 3 interim data from Part B of a pivotal study of Acoramidis - indicated for ATTR.

BridgeBio: If Acoramidis Completes Comeback, This Highly Prized Biotech's Share Price Should Soar

PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host a roundtable discussion on Thursday, February 16 at 12:00 pm ET with Melita Irving, clinical geneticist at Guy's and St Thomas' NHS Foundation Trust, London, UK and investigator for the infigratinib clinical program at the Evelina London Children's Hospital.

BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023

PALO ALTO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:

BridgeBio Pharma to Participate in February and March Investor Events

BridgeBio Pharma, Inc. has a lot of irons in the fire. Despite BridgeBio Pharma, Inc. getting approvals for two products, there's hardly any revenue.

BridgeBio Pharma: The Hub-And-Spoke Model Is Complicated And Confusing

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9 at 3:00 pm PT.

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations over a 24 week treatment period in patients with autosomal dominant hypocalcemia type 1 (ADH1)

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences:

BridgeBio Pharma to Participate in November Investor Events

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 8.82% and 94.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Reports Q3 Loss, Misses Revenue Estimates

- Reported positive preclinical data for its next-generation KRAS G12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Will BridgeBio Pharma (BBIO) Report Negative Q3 Earnings? What You Should Know

- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRAS G12C GTP/GDP dual inhibitor development candidate BBO-8520, and its novel PI3Kα:RAS breaker mechanism which is in late lead optimization

BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

PALO ALTO, Calif., Oct. 14, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and its affiliate company ML Bio Solutions, today reported 12-month data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i). These updated results were presented in an oral presentation at the 27th International Hybrid Annual Congress of the World Muscle Society (WMS), taking place in Halifax, Canada on October 11 – 15, 2022.

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

- Robust post-dosing changes continue to be seen in key markers associated with severity of disease

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

- BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination therapies given its continuous, once-daily dosing in addition to synergistic activity with other agents to treat cancers driven by KRAS G12C mutations

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen's LUMAKRAS® (sotorasib)

- The conference will take place at the National Cancer Institute at Frederick, Maryland from October 17-19, 2022

BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium

- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years.

BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

- Initial data readout for patients with PA and MMA expected in the first half of 2023

BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

- NULIBRY is the first and only approved therapy in the United States (U.S.) and in Israel to treat patients with MoCD Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 11.96% and 146.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BridgeBio Pharma (BBIO) Moves to Buy: Rationale Behind the Upgrade

- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) was + 1.52 cm/yr (p= 0.02, n=11 ) and the responder rate was 64% in children 5 years and older 1

BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial

- CHMP recommendation for approval of NULIBRY in the European Union (EU) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A is based on the efficacy and safety data collected to date compared to data from a natural history study - Under an accelerated assessment pathway, a decision by the European Commission (EC), which authorizes marketing approval in the European Union (EU), is expected on the NULIBRY application later this year - If approved by the EC, NULIBRY would be the first and only approved therapy in the EU to treat patients with MoCD type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants with a median overall survival age of about four years - NULIBRY was BridgeBio's first FDA-approved therapeutic; Sentynl acquired global rights to NULIBRY in March 2022 PALO ALTO, Calif. and SOLANA BEACH, Calif.

News for BridgeBio Pharma Inc Stock (BBIO)